Authors' Affiliations: Dana Farber/Brigham and Women's Cancer Center Department of Radiation Oncology, Harvard Medical School, Boston; Harvard Radiation Oncology Program, Boston; On-Q-ity, Inc., Waltham; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; and Dana Farber/Brigham and Women's Cancer Center Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.
Clin Cancer Res. 2010 Dec 1; 16(23):5796-804.
To evaluate the prognostic utility of immunohistochemical assessment of key proteins in multiple DNA repair pathways in triple-negative breast cancer (TNBC; estrogen receptor negative, progesterone receptor negative, and HER2/neu negative by immunohistochemistry).
Archived clinically annotated tumor specimens from 112 women with TNBC were immunostained with antibodies against DNA repair proteins and scored using digital image analysis. The cohort was divided into training and test sets for development of a multiantibody model. Scores were combined with clinical data to assess association with outcome.
Low XPF (P = 0.005), pMK2 (P = 0.01), MLH; P = 0.002), and FANCD2 (P = 0.001) were each associated with shorter time to recurrence (TTR) in univariate analysis. A 4-antibody model could segregate high-risk and low-risk groups on the basis of TTR in both the training (relative risk [RR] = 3.52; P = 9.05E-07) and test (RR 2.67; P = 0.019) cohorts.
DNA repair proteins may be useful as prognostic markers in TNBC. Further study in larger, uniformly treated cohorts with additional clinical parameters is warranted.
Clin Cancer Res; 16(23); 5796-804. ©2010 AACR.
PMID: 21138871 [PubMed - in process] Source: National Library of Medicine.
